As of December 12, 2025, the Gardasil 9 vaccine is covered by French social security at a rate of 65% for individuals up to 26 years old who were not previously vaccinated at a younger age. Coverage for subsequent doses needed to complete the vaccination schedule will continue to be reimbursed, even if administered after the patient’s 27th birthday, as long as the initial schedule was started before that age. This policy is based on vaccination recommendations from the Haute Autorité de santé (HAS) and the decree of December 9, 2025.
Gardasil 9 Required for Initial Vaccination
In line with the current vaccination schedule, all initial vaccinations against the human papillomavirus (HPV) must be administered using the nonavalent Gardasil 9 vaccine. For individuals 15 years and older, the recommended schedule involves three injections (M0, M2, M6), completed within a year. This expanded access to the vaccine is an crucial step in preventing HPV-related illnesses.
HPV infections are very common sexually transmitted infections, affecting nearly 80% of sexually active individuals during their lifetime. These infections often resolve on their own, but persistent viral infections can lead to genital lesions or precancerous conditions, particularly cervical cancer. Currently, there is no antiviral treatment available to specifically eliminate the virus.
Sources: decree of December 9, 2025, modifying the list of pharmaceutical specialties reimbursable to social security affiliates; “Vaccination against human papillomaviruses (HPV) – broadening the catch-up vaccination cohort for men and women up to 26 years old,” Haute Autorité de santé, May 2025; “The vaccine against human papillomavirus infections is now reimbursed up to 26 years old,” Assurance maladie, December 2025.
